Beating the street to market painkillers in Chicago? You might need a special license for that soon.

Bristol-Myers Squibb has gotten more bad news in its efforts to grow lung cancer sales. England's cost watchdog has turned it down, although the regulator…

Vertex won a label expansion for cystic fibrosis combo Orkambi late Wednesday--but, as expected, the company lowered its full-year guidance for the med, too.…

Congress is starting to get some answers on EpiPen pricing. And though, so far, Mylan’s not offering much beyond what’s readily available via Google search,…

Merck & Co. never got its clot-fighting drug Zontivity off the ground, and last month, the company decided to stop promoting it in the U.S. altogether. But…

Merck & Co. is officially on its way to eclipsing BMS in lung cancer. Its immuno-oncology drug Keytruda won a breakthrough tag for first-line treatment, a…

Novo Nordisk’s combination diabetes drug didn’t lap Sanofi’s after all. Two weeks after the FDA put off approval of the French drugmaker’s insulin-plus-GLP-1…

The U.K.’s promotional police cracked down on biosimilar marketing this week, citing Pfizer’s Hospira unit and Napp Pharmaceuticals for code violations at…

After a former Insys Therapeutics sales rep admitted she had paid kickbacks to doctors to prescribe the company's sprayed cancer pain opioid fentanyl for…

Regulatory